A National, Multi-Center, Open-Label, Three-Arm, Phase II Study to Investigate the Effect of Montelukast Between Emergency Room Visits and Hospitalizations in COVID-19 Pneumonia in Comparison With Standard Treatment

Durdagi et al., NCT04718285, NCT04718285, Jun 2022
32nd treatment shown to reduce risk in November 2021, now with p = 0.0041 from 9 studies.
Lower risk for hospitalization and cases.
No treatment is 100% effective. Protocols combine treatments.
6,300+ studies for 210+ treatments. c19early.org
Meta Analysis
Estimated 380 patient montelukast early treatment RCT with results not reported over 3 years after estimated completion.
2 montelukast RCTs have results missing long after expected1,2
The trials report an estimated total of 664 patients.
Important missing comments or errors? Let us know.
Durdagi et al., 1 Jun 2022, Randomized Controlled Trial, Turkey, trial NCT04718285 (history). Contact: serdar.durdagi@med.bau.edu.tr.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0